Verano Holdings (VRNO) Depreciation & Amortization (CF) (2021 - 2026)
Verano Holdings' (VRNO) quarterly Depreciation & Amortization (CF) came in at $29.2 million in Q1 2026, down 8.19% year-on-year from $31.8 million in Q1 2025, and little changed on a QoQ basis from $29.3 million in Q4 2025.
Verano Holdings (VRNO) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $29.2 million in Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) fell 8.19% year-over-year to $29.2 million in Q1 2026; TTM through Mar 2026 was $121.6 million, a 10.56% decrease from a year earlier, with the FY2025 full-year figure at $124.2 million, down 11.1% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $29.2 million, roughly flat from $29.3 million in the prior quarter.
- Over the last five years, Depreciation & Amortization (CF) for VRNO reached as high as $36.9 million in Q3 2024 and fell as low as $29.2 million in Q1 2026.
- Historically, Depreciation & Amortization (CF) has averaged $33.9 million across 5 years, with a median of $35.2 million in 2022.
- Across the five-year window, Depreciation & Amortization (CF) jumped 46.15% in 2022 and retreated 14.39% in 2025, its largest moves.
- Year by year, Depreciation & Amortization (CF) stood at $35.2 million in 2022, then grew by 1.19% to $35.6 million in 2023, then slipped by 11.41% to $31.5 million in 2024, then retreated by 6.97% to $29.3 million in 2025, then slipped by 0.44% to $29.2 million in 2026.
- Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $29.2 million in Q1 2026, $29.3 million in Q4 2025, and $31.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 29.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.19 Mn |
| Mar 31, 2026 | 29.19 Mn |
| Dec 31, 2025 | 29.32 Mn |
| Dec 31, 2025 | 29.32 Mn |
| Sep 30, 2025 | 31.56 Mn |
| Sep 30, 2025 | 31.56 Mn |
| Jun 30, 2025 | 31.49 Mn |
| Jun 30, 2025 | 31.49 Mn |
| Mar 31, 2025 | 31.79 Mn |
| Mar 31, 2025 | 31.79 Mn |
| Dec 31, 2024 | 31.51 Mn |
| Dec 31, 2024 | 31.51 Mn |
| Sep 30, 2024 | 36.87 Mn |
| Sep 30, 2024 | 36.87 Mn |
| Jun 30, 2024 | 35.73 Mn |
| Jun 30, 2024 | 35.73 Mn |
| Mar 31, 2024 | 35.55 Mn |
| Mar 31, 2024 | 35.55 Mn |
| Dec 31, 2023 | 35.57 Mn |
| Dec 31, 2023 | 35.57 Mn |